Jazz Pharmaceuticals completes acquisition of Actio Biosciences

Jazz Pharmaceuticals plc announced on September 15, 2026 that it had completed its acquisition of privately-held Actio Biosciences, Inc. for $820 million upfront.¹ Actio is now a wholly-owned subsidiary of Jazz.¹

The acquisition centers on ABS-1230, which the company describes as a potent and selective orally available small molecule KCNT1 inhibitor for the treatment of KCNT1-related epilepsy.¹ In preclinical work, ABS-1230 inhibited KCNT1 across all evaluable pathogenic mutations, indicating potential to treat all patients with KCNT1-related epilepsy.¹ In an early clinical study, children with KCNT1-related epilepsy who received ABS-1230 experienced meaningful seizure reductions.¹

The drug has already picked up several regulatory designations. Jazz said ABS-1230 has received Fast Track, Rare Pediatric Disease and Orphan Drug Product designations from the U.S. Food and Drug Administration and has been accepted into the agency's Rare Disease Evidence Principles process.¹

On the deal structure, Jazz completed the transaction through the merger of Knight Acquisition Corp., a Delaware corporation and indirect wholly-owned subsidiary of Jazz, with and into Actio, with Actio continuing as the surviving corporation and an indirect wholly-owned subsidiary of Jazz.¹ Separately, Actio spun out a new privately-held entity to which certain non-ABS-1230 programs were transferred, funded by existing investors, with Jazz receiving a minority stake and certain related rights.¹

The filing was made under Item 7.01 (Regulation FD Disclosure) of Jazz's Form 8-K dated September 15, 2026, with the press release furnished as Exhibit 99.1.